Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:country |
gptkb:China
|
| gptkbp:founded |
1970
|
| gptkbp:headquarters_location |
gptkb:Lianyungang
|
| https://www.w3.org/2000/01/rdf-schema#label |
Jiangsu Hengrui Medicine
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:keyPerson |
Sun Piaoyang
|
| gptkbp:listedSince |
2000
|
| gptkbp:marketCap |
over US$60 billion (as of 2021)
|
| gptkbp:notable_drug |
gptkb:Apatinib
gptkb:Camrelizumab Iremodulin |
| gptkbp:numberOfEmployees |
over 20,000
|
| gptkbp:parentCompany |
Hengrui Group
|
| gptkbp:products |
oncology drugs
contrast agents cardiovascular drugs surgical drugs |
| gptkbp:R&D_investment |
high
|
| gptkbp:stockExchange |
gptkb:Shanghai_Stock_Exchange
|
| gptkbp:stockSymbol |
600276
|
| gptkbp:website |
https://www.hrs.com.cn/
|
| gptkbp:bfsParent |
gptkb:camrelizumab
gptkb:Hu_Baishan gptkb:Apatinib gptkb:Camrelizumab gptkb:WuXi_Biologics |
| gptkbp:bfsLayer |
7
|